Effect of 48 Months of Closed-Loop Insulin Delivery on Residual C-Peptide Secretion and Glycemic Control in Newly Diagnosed Youth With Type 1 Diabetes: A Randomized Trial

• Published in: Diabetes care Vol. 47; no. 8; pp. 1441 - 1448
• Main Authors: Ware, Julia, Boughton, Charlotte K, Allen, Janet M, Wilinska, Malgorzata E, Hartnell, Sara, Thankamony, Ajay, Randell, Tabitha, Ghatak, Atrayee, Besser, Rachel E J, Elleri, Daniela, Trevelyan, Nicola, Campbell, Fiona M, Sibayan, Judy, Bailey, Ryan, Calhoun, Peter, Dunseath, Gareth, Hovorka, Roman
• Format: Journal Article
• Language: English
• Published: United States American Diabetes Association 01.08.2024
• Subjects: Adolescent; Algorithms; Blood Glucose - drug effects; Blood Glucose - metabolism; C-Peptide - blood; Child; Closed loops; Design standards; Diabetes; Diabetes mellitus (insulin dependent); Diabetes Mellitus, Type 1 - blood; Diabetes Mellitus, Type 1 - drug therapy; Diabetes Mellitus, Type 1 - metabolism; Diagnosis; Fasting; Female; Glucose; Glycated Hemoglobin - metabolism; Glycemic Control - methods; Humans; Hypoglycemic Agents - administration & dosage; Hypoglycemic Agents - therapeutic use; Insulin; Insulin - administration & dosage; Insulin - therapeutic use; Insulin Infusion Systems; Ketoacidosis; Male; Peptides; Randomization; Research design; Secretion; Therapy
• ISSN: 0149-5992; 1935-5548; 1935-5548
• DOI: 10.2337/dc24-0360

We evaluated the effect of long-term intensive metabolic control with hybrid closed-loop (CL) on residual C-peptide secretion and glucose control compared with standard insulin therapy in youth with type 1 diabetes over 48 months. Following the 24-month primary phase of a multicenter, randomized, parallel trial of 96 newly diagnosed youth aged 10 to 16.9 years, participants were invited to an extension phase using treatment allocated at randomization. They continued with hybrid CL using the Cambridge algorithm or standard insulin therapy (control) until 48 months after diagnosis. Analysis was by intention-to-treat. At 24 months after diagnosis, 81 participants (mean ± SD age 14 ± 2 years) continued in the extension phase (47 CL, 34 control). There was no difference in fasting C-peptide corrected for fasting glucose at 48 months between groups (CL: 5 ± 9 vs. control: 6 ± 14 pmol/L per mmol/L; mean adjusted difference -2 [95% CI -7, 4; P = 0.54]). Central laboratory HbA1c remained lower in the CL group by 0.9% (10 mmol/mol [95% CI 0.2, 1.5; 3, 17 mmol/mol); P = 0.009). Time in target range of 3.9 to 10.0 mmol/L was 12 percentage points (95% CI 3, 20; P = 0.008) higher in the CL group compared with control. There were 11 severe hypoglycemic events (6 CL, 5 control) and 7 diabetic ketoacidosis events (3 CL, 4 control) during the extension phase. Improved glycemic control was sustained over 48 months after diagnosis with CL insulin delivery compared with standard therapy in youth with type 1 diabetes. This did not appear to confer a protective effect on residual C-peptide secretion.